Under the affiliation agreement, patients and physicians at Saint Luke’s Cancer Institute will have access to approximately 175 trials of investigational therapies and 35 other cancer-related trials, according to the report. Patients involved in the trials will remain under the care of their Saint Luke’s physicians.
“Washington University School of Medicine is one of the nation’s top medical research institutions, recognized by the National Cancer Institute as a Comprehensive Cancer Center,” said Timothy Pluard, MD, medical director of the Saint Luke’s Cancer Institute. “This is a significant affiliation and offers tremendous benefit to our patients by making available a larger number of the latest NCI clinical trials.”
More articles on transactions and valuations:
CHS rejects physicians’ $2.4B offer for Lutheran Health Network
12 recent hospital transactions and partnerships
McLaren Greater Health forms pediatric care partnership with Spectrum Health children’s hospital
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
